Emergent BioSolutions | EBS - Stock


Emergent BioSolutions reported $328.9M in Stock for its fiscal quarter ending in December of 2023.





Stock Change Date
Acadia Pharmaceuticals USD 34.67M 5.57M Dec/2025
Akebia Therapeutics USD 15.61M 3.03M Dec/2025
ALKERMES USD 196.62M 5.63M Dec/2025
Alnylam Pharmaceuticals USD 82.72M 7.34M Dec/2025
Amarin USD 184.7M 13.46M Sep/2025
ANI Pharmaceuticals USD 143.07M 3.41M Dec/2025
BioMarin Pharmaceutical USD 1.3B 83.29M Dec/2025
Coherus Biosciences USD 3.17M 1.12M Dec/2025
Emergent BioSolutions USD 328.9M 25.2M Dec/2023
Exelixis USD 27.4M 3.92M Sep/2025
Glaxosmithkline GBP 6.12B 46M Sep/2025
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Ionis Pharmaceuticals USD 10.47M 1.99M Sep/2025
Lexicon Pharmaceuticals USD 168K 33K Jun/2025
Lonza CHF 1.68B 163M Dec/2025
Merck USD 6.44B 157M Sep/2025
Moderna USD 332M 92M Sep/2025
Myriad Genetics USD 30.6M 1000K Dec/2025
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 69M 300K Dec/2025
Pacira USD 152.86M 4.82M Dec/2025
Pfizer USD 11.47B 201M Sep/2025
PTC Therapeutics USD 79.65M 26.96M Dec/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Sarepta Therapeutics USD 914.74M 162.42M Dec/2025
United Therapeutics USD 183.1M 6.6M Dec/2025
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025